The Coenzyme Q10 Supplementation Effects on Lipid Profile, Fasting Blood Sugar, Blood Pressure and Oxidative Stress Status Among Non-Alcoholic Fatty Liver Disease Patients: A Randomized, Placebo-Controlled, Pilot Study

Abstract

AIM: Non-alcoholic fatty liver disease (NAFLD) is a major cause of hepatic disorders and its prevalence is increasing in both adults and children worldwide. Coenzyme Q10 (CoQ10) is a well-known naturally pro-vitamin and is acting as a primary scavenger of free radicals. Our work is aimed at exploring the therapeutic potential of CoQ10 supplementation against NAFLD. METHODS: 41 patients with NAFLD were randomly allocated to 2 groups: the CoQ10 group (n=20) received 100 mg oral CoQ10 supplement daily and the control group (n=21) received 100 mg starch daily as placebo, for a 12-weeks period. RESULTS: After 12 weeks of intervention, there were a significant decrease in systolic blood pressure (before=123.90±13.05, after=114.89±14.21, P<0.05) in the CoQ10 group, while diastolic blood pressure did not decrease significantly in either of the two groups as compared to the baseline measurement. In addition, no significant reduction observed at the level of malondialdehyde, lipid profile and fasting blood sugar after 12 weeks of supplementation in either of the groups. CONCLUSION: According to the results of this study, the CoQ10 antioxidant supplementation at a dosage of 100 mg/d could significantly improve systolic blood pressure without any effect on the DBP, lipid profiles, FBS and oxidative stress status in the patients with the NAFLD. We recommend the data of this study be further verified by clinical trials.